COVID-19 didn’t disappear. The virus still circulates globally, still hospitalizes people, and still kills, but the emergency phase is over and the way we live with it has fundamentally changed. The World Health Organization lifted its Public Health Emergency of International Concern in May 2023, and governments worldwide have shifted from crisis response to treating COVID-19 as a persistent respiratory illness managed through routine health systems.
What changed is nearly everything around the virus: the rules, the funding, the testing infrastructure, the public attention. Here’s where things actually stand.
The Emergency Is Over, but the Virus Isn’t
The U.S. Public Health Emergency officially expired on May 11, 2023, ending the legal framework that had supported free testing, free treatments, and expanded insurance coverage. The WHO ended its global emergency declaration the same month. These weren’t declarations that the virus was gone. They were acknowledgments that the acute crisis phase, defined by overwhelmed hospitals and a largely unvaccinated population, had passed.
COVID-19 still causes significant illness. During the October 2023 through April 2024 surveillance period, the CDC identified over 40,000 COVID-associated hospitalizations across 12 monitored states alone. That said, hospitalization rates across all adult age groups during that period were the lowest recorded for any October-to-April window since surveillance began in 2020-2021. The virus has settled into a pattern: weekly hospitalization rates climb through November and December, peak in late December or early January, then decline. Roughly 25% of hospitalizations occur during the warmer months of May through September. Adults 65 and older still face hospitalization rates many times higher than younger age groups.
The Virus Keeps Changing
SARS-CoV-2 continues to mutate and produce new variants. As of early 2026, the CDC’s genomic surveillance shows a landscape dominated by a family of lineages called XFG, which collectively account for roughly 65% of circulating virus. The next most common lineage, NB.1.8.1, makes up about 21%. Several other lineages circulate at lower levels. None of these have triggered a return to emergency conditions, but each new variant can shift how well vaccines and prior immunity hold up, which is why surveillance continues.
The CDC tracks variant proportions through genomic sequencing, updating estimates every four weeks. This data, combined with wastewater monitoring, emergency department visit percentages, and hospitalization networks, forms the backbone of how public health officials now watch for trouble. Individual case counts became less reliable as widespread testing dropped off, so these alternative signals carry more weight.
How the Rules Changed
In March 2024, the CDC overhauled its isolation guidance, replacing the rigid five-day isolation period with a simpler, symptom-based approach that applies to COVID-19, flu, and other respiratory viruses equally. You can return to normal activities once your symptoms have been improving for at least 24 hours and any fever has been gone for 24 hours without fever-reducing medication. For the following five days, the CDC recommends extra precautions: wearing a well-fitting mask, improving ventilation, keeping distance from others when possible, and considering a test.
This shift was deliberate. Public health officials wanted a single, practical framework people might actually follow rather than virus-specific rules that had become increasingly difficult to enforce or track.
What Testing and Treatment Cost Now
The end of the Public Health Emergency reshuffled who pays for what. At-home COVID tests may no longer be covered by your insurance, though the CDC maintains a system to help people find free testing sites. If you have private or public insurance, COVID vaccines remain covered at no cost. People without insurance face the biggest change: once federally purchased vaccine supplies run out, the cost falls on them.
The antiviral treatment Paxlovid, which reduces the risk of hospitalization and death when taken within five to seven days of symptom onset, is no longer universally free. If you’re uninsured or underinsured, you can still receive it at no cost through a government patient assistance program, which runs until U.S. government supplies are depleted or December 31, 2028, whichever comes first. For those with insurance, coverage varies by plan. Another antiviral, molnupiravir, is no longer available through government distribution as all supplied courses have expired.
Treatment is still recommended for anyone with mild or moderate COVID who has risk factors for severe disease, including older age, obesity, diabetes, heart disease, or a weakened immune system. The key is starting early, within that five-to-seven-day window from symptom onset.
Long COVID Remains a Major Issue
Perhaps the most significant ongoing consequence of the pandemic is Long COVID. In 2023, 6.4% of U.S. adults reported experiencing Long COVID symptoms at the time they were surveyed. That translates to millions of people dealing with persistent problems, fatigue, brain fog, shortness of breath, joint pain, and other symptoms lasting three months or longer after their infection that weren’t present before they had COVID.
For some, these symptoms significantly limit daily activities. Long COVID doesn’t discriminate neatly by age or severity of the original infection, though certain groups are at higher risk. Research into treatments and underlying mechanisms continues, but there is no single approved therapy for the condition. For many people searching “what happened to COVID,” Long COVID is a daily, personal answer: it never left.
Vaccines Now Work Like Flu Shots
COVID vaccination has shifted to an annual update model, similar to the flu shot. For fall 2024, the FDA recommended a formula targeting the KP.2 strain from the JN.1 lineage, chosen because it more closely matched the variants circulating at that time. The goal is the same as with flu vaccines: update the formula each year to keep pace with viral evolution, even knowing the match won’t be perfect by the time the next wave hits.
Uptake has dropped significantly compared to the early rollout in 2021, when demand far outstripped supply. The CDC monitors vaccination rates and confidence through its COVIDVaxView surveys, and the numbers reflect a public that has largely moved on from the urgency of the pandemic’s first years.
How COVID Is Tracked Now
With fewer people testing at clinics and reporting results, public health agencies have leaned into other surveillance tools. Wastewater monitoring, which detects viral genetic material in sewage, provides a population-level snapshot of how much virus is circulating in a community regardless of whether individuals get tested. Emergency department data shows what percentage of visits involve COVID. Hospitalization networks like COVID-NET track severe cases across multiple states. And genomic surveillance sequences samples to identify which variants are spreading.
Together, these systems give health officials a reasonable picture of COVID activity without relying on the mass individual testing that defined 2020 and 2021. The tradeoff is less precision at the individual level. You’re less likely to know your neighbor had COVID, but public health agencies can still detect surges early enough to respond.